Another beat, navigated by mature drugs and R&D caps
18/08/17 -"Lundbeck reported strong Q2 17 results, ahead of consensus as well as our estimates (significant beat on profitability). Revenue increased 14% yoy to DKK4.3bn (+15% at LC), driven by the continued ..."
Pages
51
Language
English
Published on
18/08/17
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...